2月10日,基石药业-B股(02616)盘中大涨5.08%,引发市场关注。
消息面上,高盛发布研究报告,将基石药业旗下的创新抗体偶联药物CS5001列为2025年值得期待的全球授权合作项目之一。报告认为,CS5001全球总可及市场超过430亿美元,基石药业在该领域拥有明显的竞争优势。预计基石药业在今年美国临床肿瘤学会年会上将公布CS5001的临床试验数据,并积极寻求全球范围内的授权合作。
CS5001临床前景备受市场看好,有望为基石药业打开全球市场,实现更大发展。这也增强了投资者对基石药业长期增长潜力的信心,导致其股价当日大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.